Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Dapagliflozin50 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00170 | 35202771 | Diabetes Res Clin Pract | Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00217 | 35181350 | Diabetes Res Clin Pract | Metabolic Changes Induced by Dapagliflozin, an SGLT2 Inhibitor, in Japanese Patients with Type 2 Diabetes Treated by Oral Anti-diabetic Agents: A Randomized, Clinical Trial. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00701 | 34998036 | Int Immunopharmacol | Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. | 2022 | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | 2021 | Details |
| A01964 | 34550043 | Adipocyte | Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice. | 2021 | Details |
| A02788 | 34239714 | Oman Med J | Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. | 2021 | Details |
| A02838 | 34224699 | Eur J Pharmacol | Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. | 2021 | Details |
| A03106 | 34129252 | J Gastroenterol Hepatol | The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A03117 | 34123670 | Cureus | Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. | 2021 | Details |
| A03197 | 34093169 | Front Pharmacol | Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway. | 2021 | Details |
| A03398 | 34016738 | J Investig Med | Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease. | 2021 | Details |
| A03745 | 33879970 | J Clin Biochem Nutr | Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. | 2020 | Details |
| A04769 | 33511282 | Clin Exp Hepatol | SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. | 2020 | Details |
| A04892 | 33464703 | Diabetes Obes Metab | Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. | 2021 | Details |
| A04904 | 33457424 | J Diabetes Res | Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. | 2020 | Details |
| A05042 | 33396949 | Metabolites | Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | 2020 | Details |
| A05758 | 33131199 | J Diabetes Investig | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. | 2020 | Details |
| A06861 | 32719069 | J Pharmacol Exp Ther | The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. | 2020 | Details |
| A07150 | 32599319 | Int Immunopharmacol | Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver. | 2020 | Details |
| A07401 | 32514450 | JGH Open | Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. | 2019 | Details |
| A07866 | 32329963 | J Diabetes Investig | Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. | 2020 | Details |
| A08288 | 32168769 | Int J Mol Sci | Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08426 | 32115853 | Diabetes Obes Metab | A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. | 2020 | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 | Details |
| A09120 | 31867105 | Cancer Metab | SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. | 2019 | Details |
| A09381 | 31769484 | Clin Sci (Lond) | Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. | 2019 | Details |
| A09569 | 31692226 | Diabetes Obes Metab | Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. | 2019 | Details |
| A09583 | 31686884 | Diabetes Metab Syndr Obes | Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. | 2019 | Details |
| A10769 | 31202833 | Metabolism | Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. | 2019 | Details |
| A11204 | 31000862 | J Pak Med Assoc | Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. | 2019 | Details |
| A11215 | 30993553 | Clin Drug Investig | Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2019 | Details |
| A11635 | 30810254 | Int J Clin Pract | Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. | 2019 | Details |
| A12911 | 30229578 | Endocrinol Metab (Seoul) | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease. | 2018 | Details |
| A13020 | 30178600 | Diabetes Obes Metab | Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. | 2018 | Details |
| A13075 | 30149145 | Diabetes Metab | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. | 2018 | Details |
| A13443 | 29971527 | Diabetologia | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. | 2018 | Details |
| A19328 | 26628836 | J Clin Exp Hepatol | Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. | 2015 | Details |
| A19739 | 26381272 | Diabetes Metab Res Rev | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. | 2015 | Details |
| A32233 | 28912902 | Curr Ther Res Clin Exp | Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. | 2017 | Details |
| A43014 | 32812927 | Metabol Open | Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. | 2020 | Details |
| A43281 | 32072735 | Diabetes Obes Metab | Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. | 2020 | Details |
| A47692 | 33626870 | J Med Chem | Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats. | 2021 | Details |
| A47963 | 28008402 | ACG Case Rep J | Dapagliflozin-Induced Acute-on-Chronic Liver Injury. | 2016 | Details |
| A49867 | 35614469 | Cardiovasc Diabetol | The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. | 2022 | Details |
| A50567 | 35338446 | Diabetes Ther | Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications. | 2022 | Details |
| A50630 | 35321843 | Clin Res Hepatol Gastroenterol | Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A51891 | 33432553 | J Endocrinol Invest | Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. | 2021 | Details |
| A52310 | 28811292 | Am J Physiol Endocrinol Metab | Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. | 2017 | Details |